Breaking the therapeutic ceiling in drug development in ulcerative colitis.
Journal
The lancet. Gastroenterology & hepatology
ISSN: 2468-1253
Titre abrégé: Lancet Gastroenterol Hepatol
Pays: Netherlands
ID NLM: 101690683
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
03
01
2021
revised:
15
02
2021
accepted:
18
02
2021
pubmed:
22
5
2021
medline:
17
8
2021
entrez:
21
5
2021
Statut:
ppublish
Résumé
Increased knowledge of the intricate pathogenesis of ulcerative colitis has triggered an advance in drug development during the past two decades, resulting in the advent of several biological agents and small-molecule therapies. Although the increase in therapeutic options is positive, remission rates of patients with ulcerative colitis given new therapeutic agents in induction trials remain at a modest 20-30%, seemingly facing a so-called therapeutic ceiling. This therapeutic ceiling requires a critical appraisal and highlights the need for alternative strategies for drug development. In this Review, we objectively itemise the boundaries of therapeutic efficacy in ulcerative colitis, provide possible explanations for the shortcomings of current strategies, and propose solutions to achieve better therapeutic outcomes in ulcerative colitis.
Identifiants
pubmed: 34019798
pii: S2468-1253(21)00065-0
doi: 10.1016/S2468-1253(21)00065-0
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
589-595Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK097948
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests BV reports financial support for research from Pfizer; lecture fees from Abbvie, Biogen, Chiesi, Falk, Ferring, Galapagos, Janssen, MSD, Pfizer, R-Biopharm, Takeda, and Truvion; and consultancy fees from Janssen, Guidepont, and Sandoz. SV reports financial support for research from MSD, AbbVie, Takeda, Pfizer, Johnson & Johnson; lecture fees from MSD, AbbVie, Takeda, Ferring, Centocor, Hospira, Pfizer, Johnson & Johnson, and Genentech and Roche; and consultancy fees from MSD, AbbVie, Takeda, Ferring, Centocor, Hospira, Pfizer, Johnson & Johnson, Genentech and Roche, Celgene, Mundipharma, Celltrion, SecondGenome, Prometheus, Shire, Prodigest, Gilead, and Galapagos. CF received speaker fees from UCB, Sandoz, Janssen, and Genentech; consultancy fees from Athos Therapeutics; and grants from US National Institutes of Health (P30 DK097948-06 and T32DK083251-11). DA declares no competing interests.